NDA 207078 · Astrazeneca
Lokelma
Sodium Zirconium Cyclosilicate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Feb 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
May 18, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
35
17 Phase 3, 5 recruiting
FAERS reports
4,008
3,277 serious, 1,441 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 11, 2026.
LOKELMA is indicated for the treatment of hyperkalemia in adults. Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) and Clinical Studies (14) ] . LOKELMA is a potassium binder indicated for the treatment of hyperkalemia in adults. ( 1 ) Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. ( 1 )
Mechanism: LOKELMA (sodium zirconium cyclosilicate) is a non-absorbed zirconium silicate that preferentially captures potassium in exchange for hydrogen and sodium. In vitro , LOKELMA has a high affinity for potassium ions, even in the presence of other cations such as calcium and magnesium. LOKELMA increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, thereby lowering serum potassium levels.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 24, 2020 Supplement 3 · Efficacy LabelLetter
- May 18, 2018 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
2 products under this application
- LOKELMA · SODIUM ZIRCONIUM CYCLOSILICATE 5GM/PACKET · FOR SUSPENSION, ORAL · Prescription · TE AB
- LOKELMA · SODIUM ZIRCONIUM CYCLOSILICATE 10GM/PACKET · FOR SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Zirconium Cyclosilicate" as an intervention, any sponsor and status, largest first.
- Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)Pivotal-lookingTerminated
AstraZenecaAstraZeneca (AZN)
NCT04847232 · 2,690 participants · Start Apr 30, 2021 · Primary completion Mar 7, 2024
Drug: Sodium Zirconium Cyclosilicate (SZC); SZC Placebo · For: Hyperkalemia
Sites: Huntsville, Alabama; Mesa, Arizona; Bakersfield, California · 340 sites in all
- A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of HyperkalaemiaPivotal-lookingTerminated
AstraZenecaAstraZeneca (AZN)
NCT05056727 · 1,112 participants · Start Sep 30, 2021 · Primary completion Feb 7, 2024
Drug: Sodium Zirconium Cyclosilicate (SZC); Placebo and 3 more · For: Renal Insufficiency, Chronic; Hyperkalemia
Sites: Surprise, Arizona; Tucson, Arizona; Canyon Country, California · 276 sites in all
- Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 MonthsPivotal-lookingCompleted
ZS Pharma, Inc.Industry
NCT02163499 · 751 participants · Start Jun 30, 2014 · Primary completion Nov 30, 2016
Drug: Sodium Zirconium Cyclosilicate · For: Hyperkalemia
Sites: Scottsboro, Alabama; Tempe, Arizona; Tucson, Arizona · 50 sites in all
- Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving SpironolactonePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04676646 · 366 participants · Start Mar 8, 2021 · Primary completion Jul 15, 2024
Drug: Sodium zirconium cyclosilicate; Placebo · For: Hyperkalaemia; Heart Failure With Reduced Ejection Fraction
Sites: Fairhope, Alabama; Los Angeles, California; Torrance, California · 89 sites in all
- A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT03528681 · 270 participants · Start May 6, 2021 · Primary completion Sep 15, 2022
Drug: Sodium Zirconium Cyclosilicate 5g; Sodium Zirconium Cyclosilicate 10g and 1 more · For: Hyperkalemia
Sites: Baotou, China; Beijing, China; Bengbu, China · 66 sites in all
- A Study to Investigate the Safety and Efficacy of ZS in Patients With HyperkalemiaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02875834 · 267 participants · Start Mar 3, 2017 · Primary completion Feb 14, 2018
Drug: Sodium Zirconium Cyclosilicate (ZS) 10g; Sodium Zirconium Cyclosilicate (ZS) 5g and 2 more · For: Hyperkalemia
Sites: Chiba, Japan; Hanyu-shi, Japan; Hitachi-Naka, Japan · 45 sites in all
- Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.Pivotal-lookingCompleted
ZS Pharma, Inc.Industry
NCT02088073 · 258 participants · Start Mar 31, 2014 · Primary completion Aug 31, 2014
Drug: Sodium zirconium cyclosilicate; Placebo · For: Hyperkalemia
Sites: Anniston, Alabama; Huntsville, Alabama; Scottsboro, Alabama · 46 sites in all
- A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT03303521 · 196 participants · Start Dec 14, 2017 · Primary completion Nov 7, 2018
Drug: Placebo; Sodium Zirconium Cyclosilicate (ZS) · For: Hyperkalemia
Sites: Los Angeles, California; Ontario, California; San Dimas, California · 53 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death1,159
- blood potassium increased206
- hyperkalaemia186
- diarrhoea180
- constipation127
- off label use127
- cardiac failure95
- nausea94
- renal failure94
- vomiting89
- acute kidney injury84
- pneumonia80
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 10 |
| 2019 | 112 |
| 2020 | 200 |
| 2021 | 262 |
| 2022 | 387 |
| 2023 | 541 |
| 2024 | 828 |
| 2025 | 863 |
| 2026 | 805 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lokelma (Sodium Zirconium Cyclosilicate)
2024 spending
$239M
Beneficiaries
116,877
334,671 claims
Per beneficiary
$2,045
$26.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $48,507,096 |
| 2021 | $100,112,117 |
| 2022 | $160,327,812 |
| 2023 | $205,055,771 |
| 2024 | $239,002,704 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sodium zirconium cyclosilicate in hyperkalemia.
Packham DK, Rasmussen HS, Lavin PT, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Comparative Study
- Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
Kosiborod M, Rasmussen HS, Lavin P, et al. · JAMA 2014 · Clinical Trial, Phase III, Multicenter Study
- Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure.
Kosiborod MN, Cherney DZI, Desai AS, et al. · J Am Coll Cardiol 2025 · Randomized Controlled Trial, Multicenter Study
- A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
Fishbane S, Ford M, Fukagawa M, et al. · J Am Soc Nephrol 2019 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE.
Roger SD, Spinowitz BS, Lerma EV, et al. · Am J Nephrol 2019 · Clinical Trial, Phase III, Multicenter Study
- Updates in chronic kidney disease management: A systematic review.
Ammar A, Edwin SB, Whitney R, et al. · Pharmacotherapy 2025 · Systematic Review
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.